A Meta Analysis Of Gemcitabine For Recurrent Ovarian Cancer

[Objective] :To assess the clinical efficacy and safety of gemcitabine for recurrent epithelial ovarian cancer compared to other anti-cancer agents.[Method] :The following electronic databases were searched: MEDLINE (1966-2008),EMBASE( 1989-2008),Cochrane(1966-2008)by English and CNKI(1994-2008) by Chinese. The related articles and information in the libraries and on the Internet,such as Google ,baidu, were searched by hand. RCTs of chemotherapy comparing gemcitabine with other agents for recurrent epithelial ovarian cancer were included.[Results] :Three RCTs met the inclusion criteria. The one of the RCTs aims to compare GEM with PLD in the efficacy and safety;another RCT has an access to compare GEM and carboplatin therapy with single carboplatin in the efficacy and safety of plastinum-sensitive ovarian cancer;the last RCT shows the differences between GEM and PLD in the efficacy and safety. GEM is the same as PLD in clinical benefit rate,but more significantly higher than PLD in the 3/4 neutropenia .Compared with single carboplatin therapy, GEM and carboplatin therapy has a sound clinical benefit rate and a worse hematological toxicity. [Conclusion]: In the ROC chemotherapy, GEM and PLD are considerated equallyeffitive, but GEM is more prone to neutropenia than PLD. In platinum-sensitiverecurrent ovarian cancer treatment, GEM and carboplatin treatment are more effectivethan single carboplatin drug treatment, but significantly increased hematologicaltoxicity.